SPR 720

Drug Profile

SPR 720

Alternative Names: SPR-720

Latest Information Update: 12 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Spero Therapeutics
  • Class Antibacterials
  • Mechanism of Action DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mycobacterial infections; Tuberculosis

Most Recent Events

  • 02 Apr 2018 Spero Therapeutics plans a phase I trial for Mycobacterial infections in first half of 2019
  • 04 May 2017 Spero Therapeutics receives SBIR grant from NIH for SPR 720 development in Tuberculosis
  • 04 May 2017 Preclinical trials in Tuberculosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top